HCT characteristics
| Variable . | Parous sibling . | Male URD . | P . |
|---|---|---|---|
| Time from diagnosis to transplant, median (range), mo | 5 (<1-153) | 7 (<1-291) | <.001 |
| Time from diagnosis to transplant, n (%), mo | <.001 | ||
| <6 | 492 (55) | 821 (43) | |
| 6-12 | 197 (22) | 522 (27) | |
| >12 | 203 (23) | 574 (30) | |
| Missing | 0 | 4 (<1) | |
| Graft type, n (%) | <.001 | ||
| BM | 118 (13) | 462 (24) | |
| Peripheral blood | 774 (87) | 1459 (76) | |
| Conditioning regimen intensity, n (%) | .38 | ||
| Myeloablative | 673 (75) | 1403 (73) | |
| TBI | 341 (51) | 685 (49) | |
| No TBI | 332 (49) | 718 (51) | |
| Reduced intensity | 165 (18) | 385 (20) | |
| TBI | 31 (19) | 67 (17) | |
| No TBI | 134 (81) | 318 (83) | |
| Nonmyeloablative | 54 (6) | 133 (7) | |
| TBI | 51 (95) | 122 (92) | |
| No TBI | 3 (5) | 11 (8) | |
| GVHD prophylaxis, n (%) | <.001 | ||
| Tac + MTX | 266 (30) | 834 (43) | |
| Tac + MTX + others | 29 (3) | 176 (9) | |
| Tac ± others | 121 (14) | 365 (19) | |
| CsA + MTX | 310 (35) | 278 (14) | |
| CsA ± others | 128 (14) | 191 (10) | |
| Others* | 36 (4) | 76 (4) | |
| Missing | 2 (<1) | 1 (<1) | |
| Year of transplant, n (%) | <.001 | ||
| 2000-2003 | 255 (29) | 317 (17) | |
| 2004-2008 | 375 (42) | 1119 (58) | |
| 2009-2012 | 262 (29) | 485 (25) | |
| Variable . | Parous sibling . | Male URD . | P . |
|---|---|---|---|
| Time from diagnosis to transplant, median (range), mo | 5 (<1-153) | 7 (<1-291) | <.001 |
| Time from diagnosis to transplant, n (%), mo | <.001 | ||
| <6 | 492 (55) | 821 (43) | |
| 6-12 | 197 (22) | 522 (27) | |
| >12 | 203 (23) | 574 (30) | |
| Missing | 0 | 4 (<1) | |
| Graft type, n (%) | <.001 | ||
| BM | 118 (13) | 462 (24) | |
| Peripheral blood | 774 (87) | 1459 (76) | |
| Conditioning regimen intensity, n (%) | .38 | ||
| Myeloablative | 673 (75) | 1403 (73) | |
| TBI | 341 (51) | 685 (49) | |
| No TBI | 332 (49) | 718 (51) | |
| Reduced intensity | 165 (18) | 385 (20) | |
| TBI | 31 (19) | 67 (17) | |
| No TBI | 134 (81) | 318 (83) | |
| Nonmyeloablative | 54 (6) | 133 (7) | |
| TBI | 51 (95) | 122 (92) | |
| No TBI | 3 (5) | 11 (8) | |
| GVHD prophylaxis, n (%) | <.001 | ||
| Tac + MTX | 266 (30) | 834 (43) | |
| Tac + MTX + others | 29 (3) | 176 (9) | |
| Tac ± others | 121 (14) | 365 (19) | |
| CsA + MTX | 310 (35) | 278 (14) | |
| CsA ± others | 128 (14) | 191 (10) | |
| Others* | 36 (4) | 76 (4) | |
| Missing | 2 (<1) | 1 (<1) | |
| Year of transplant, n (%) | <.001 | ||
| 2000-2003 | 255 (29) | 317 (17) | |
| 2004-2008 | 375 (42) | 1119 (58) | |
| 2009-2012 | 262 (29) | 485 (25) | |
CsA, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; Tac, tacrolimus; TBI, total body irradiation.
Tac + CsA + MTX (n = 32), posttransplant cyclophosphamide (n = 25), Tac + CsA + MTX + MMF (n = 13), Tac + CsA + MMF (n = 12), Tac + CsA + MTX + others (n = 6), Tac + CsA + MMF + others (n = 2), Tac + CsA + others (n = 7), MTX + others (n = 5), MTX (n = 2), MMF (n = 3), MMF + others (n = 3), Siro (n = 1), steroids (n = 1).